ZERIA PHARMCEUTICAL CO., LTD. (4559) Stock Price

Zeria Pharmaceutical Co., Ltd. operates three main business segments: prescription pharmaceuticals, consumer healthcare, and other businesses. Through these segments, the company provides a wide range of pharmaceutical and health-related products.

In the prescription pharmaceuticals business, Zeria Pharmaceutical manufactures, procures, and sells prescription drugs. Tillotts Pharma AG primarily handles manufacturing and sales of prescription pharmaceuticals, with seven subsidiaries including Tillotts Pharma AB managing sales operations. Zeliaup Co., Ltd. handles sales promotion activities.

In the consumer healthcare business, Zeria Pharmaceutical manufactures, procures, and sells over-the-counter medications and health foods. Zeria Healthway Co., Ltd. sells health foods and cosmetics, while Iona International Co., Ltd. manufactures and sells cosmetics. ZPD A/S handles manufacturing and sales of pharmaceutical raw materials.

In other businesses, Zevis Co., Ltd. operates insurance agency and real estate operations, Zeria Shoji Co., Ltd. procures and sells promotional materials, and Zeria Ecotech Co., Ltd. provides various maintenance services. Through these operations, Zeria Pharmaceutical achieves diversified business expansion.

Zeria Pharmaceutical Co., Ltd. is guided by the fundamental principle of "Building Health, Building Happiness." The company contributes to improving quality of life through research, development, manufacturing, and sales of prescription pharmaceuticals and consumer healthcare products. It aims to provide products that address international medical needs and pursue sound management that respects social norms while meeting stakeholder trust and expectations.

Zeria Pharmaceutical's growth strategy centers on balanced management of its prescription pharmaceutical and consumer healthcare businesses. These core operations drive revenue and support sustainable growth. The company focuses particularly on research and development of gastrointestinal-focused prescription pharmaceuticals and product development that supports self-medication.

Under its 11th Medium-Term Management Plan (fiscal 2023–2025), Zeria Pharmaceutical aims to accelerate global expansion and business growth. The company is focusing on business expansion in Europe and Asia through M&A and strategic alliances to enhance corporate value. It is particularly concentrating on market expansion for "Dificlir" and "Asacol."

In the domestic market, the company seeks to expand both its prescription pharmaceutical and consumer healthcare businesses. It is allocating sales resources to proprietary products such as "Acofide" and "Ferinject" to strengthen market presence. The company also aims to capture inbound demand and strengthen advertising activities to drive sales growth of its core product portfolio.

In research and development, the company is strengthening collaboration with Tillotts Pharma AG and advancing new development projects. It is progressing development of "Z-100" and "ZG-802" to enhance product value. Through business integration, the company seeks to consolidate and streamline management resources while improving service quality. It is advancing its corporate governance framework and contributing to the realization of a sustainable society.